Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase I/II Study of CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Solid Tumors, including Pancreatic Cancer

Summary

The purpose of this phase I/II study is to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity of BA3011, a conditionally active biologic (CAB) AXL-targeted antibody drug conjugate (CAB-AXL-ADC), alone or in combination with nivolumab, in patients with advanced solid tumors, including pancreatic cancer.

General Information

NCT#: NCT03425279
Study ID: BA3011-001
Trial Phase: Phase I/II

Trial Sponsor: BioAtla, LLC
Therapies Used in This Trial: Nivolumab, BA3011

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search